FINWIRES · TerminalLIVE
FINWIRES

SGX:T14

4 stories mentioning SGX:T14Updated 16d ago

Every FINWIRES story that references SGX:T14, newest first.

Asia

Tianjin Pharmaceuticals Warns of Up to 68% Plunge in H1 Profit

Tianjin Pharmaceuticals Da Ren Tang's (SGX:T14) expects first-half net profit attributable to shareholders to slump 66% to 68% year on year to between 620 million yuan and 660 million yuan.The company attributed the sharp drop to the absence of a 1.31 billion yuan after-tax one-off gain recorded in the first half of 2025 from the disposal of its remaining 12% stake in Tianjin TSKF Pharmaceutical.Excluding non-recurring items, the company expects first-half net profit to increase 2% to 9% to between 610 million yuan and 650 million yuan,it said.

SGX:T14
Asia

Chinese State-Backed Entities to Dispose of Stake in Tianjin Pharmaceutical Da Ren Tang Unit via Public Tender

Tianjing Pharmaceutical Da Ren Tang Group's (SGX:T14) controlling shareholder, Tianjin Pharmaceutical, revealed that state-backed Chinese holding firms, SIIC Holdings and SIIC Investment Development, will sell their entire 100% stake in Shanghai Liuliguang Medical Development.Shares of the pharmaceutical company were down under 1% in Wednesday trading.The disposal will be carried out via a public tender on the Shanghai United Assets and Equity Exchange (SUAEE), according to a Tuesday filing with the Singapore Exchange.Presently, Liuliguang Medical controls a 35% equity position in Jinhushen Biological Medical Science and Technology. Jinhushen, in return, holds a dominant 67% stake in the group's direct parent company, Tianjin Pharmaceutical Holdings, which retains an absolute 43.008% stake in Da Ren Tang itself.

SGX:T14
Asia

Singapore Shares Surge More Than 1% as DBS Books Record Total Income

Singapore shares zoomed over 1% at the close on Thursday, with the market buoyed by DBS (SGX:D05) driving investor sentiment after posting record net income for the first quarter of the year.The Straits Times Index (STI), a key benchmark for the Singapore Exchange, ranged between 4,880.67 and 4,917.19 throughout the day. It ended the session at 4,912.69, up 51.72 points or 1.1% compared to Wednesday's close.The bank's shares closed over 3% higher with its total income up 1% year over year to SG$5.95 billion from SG$5.91 billion.Meanwhile, Asian markets remained positive, boosted by progress made by Japan and the US over tariff negotiations.In economic news, Singapore's manufacturing prices jumped 20.3% year over year in March, extending the 5.4% increase in the previous month, the city-state's Department of Statistics reported.Meanwhile, Singapore's Export Price Index rose 8.4% year on year in March, reversing a 4.2% decline in the preceding month.Singapore's total employment grew by 5,000 during the first quarter of the year, compared to 2,300 a year earlier, marking the 18th consecutive quarter of job growth, according to preliminary data from the Ministry of Manpower.Lending activity in Singapore expanded in March, with total loans and advances to residents rising to SG$902.3 billion from SG$893.6 billion in February, according to preliminary data released by the Monetary Authority of Singapore.In other corporate news, Tianjin Pharmaceuticals Da Ren Tang's (SGX:T14) shares were up nearly 7% at the close as its net attributable profit to owners during the first quarter of the year jumped by 13% to 423.8 million yuan from 374.2 million yuan a year earlier.

^STISGX:D05SGX:T14
Asia

Tianjin Pharmaceuticals Da Ren Tang's Attributable Profit Jumps 13% in Q1; Shares Up 5%

Tianjin Pharmaceuticals Da Ren Tang's (SGX:T14) net attributable profit to owners during the first quarter of the year jumped by 13% to 423.8 million yuan from 374.2 million yuan a year earlier, according to a Wednesday filing with the Singapore Exchange.Shares of the pharmaceutical company rose nearly 5% in Thursday trading.Earnings per share came in at 0.55 yuan compared with 0.49 yuan in the year-ago period.Revenue increased by 4% year over year to 1.52 billion yuan from 1.46 billion yuan, backed by increased revenue from major product lines.

SGX:T14

Track with the FINWIRES app suite